— Why it moved
Why CRVO Stock Tripled Today — June 16, 2026
A $10.5M lifeline plus a $3M insider buy from Vertex's founder took this 6M-float biotech from $2.48 to $7.45 by lunch, before it gave back nearly 40%.
What moved CRVO stock
CervoMed is a ~$20M biotech with an FDA-aligned Phase 3 path for neflamapimod in dementia with Lewy bodies, but no partner and, until this filing, not much cash. Two filings stacked: a $10.5M private placement pushed the cash runway into Q2 2027, and a Form 4 showed board member Joshua Boger — the founder of Vertex — buying 955,000 shares for about $3M. An insider buy that size in a $20M biotech gets noticed fast.
The mechanics
Roughly 6.3M shares in the float and 200M traded, so the float turned over about 30 times. A real filing plus a tiny float is how a stock triples in a session.
CRVO by the numbers
The alert window
Stock Pulse alerted at 11:05 AM at $4.71; the peak $7.45 printed at 12:39 PM — an hour and 34 minutes of window, worth 58% at the top. The peak was genuinely catchable: 1.5M shares traded in that minute alone.
How CRVO's move ended
Then the air came out, and it closed at $4.52, 4.1% under the alert — plus 58% at the peak, minus 4% at the close. Timing decided everything. The financing is dilution even when the press release calls it runway, and insider buying is a datapoint, not a Phase 3 result; the trial still needs a partner to fund it.
The tell: even on a real catalyst, a tiny-float spike is a window to exit through, not a level that holds into the close.